Every officer and director reconciles for this period.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
What stands out
Two insiders sold more than 25% of vested holdings: Manuel Alba (35% of holdings, $183M, all under a disclosed plan) and Philip Mazzara (40% of holdings, $11.1M, 36% under a disclosed plan).Manuel Alba: largest sale, Sep 1, 2026 · Philip Mazzara: largest sale, May 18, 2026
Bethany Mayer sold 686 shares (11% of starting holdings), but 837 more vested, so the stake grew (from 6.2K to 6.4K).Largest sale, Jun 24, 2026
Percentages cover 11 of 12 officers and directors. Left out: Desmond Lynch (held no vested shares at the start). Disclosed company stock is not an insider's whole wealth.
Who sold, and how much of their stake
Officers and directors, past 12 months. Each bar is the insider's vested stake at the start of the period (Oct 8, 2025). The gold part is what they sold.
SoldRest of starting stakeAdded during the period
Sanjay Gajendra
President and COO, Director
15% · $319M76% planned
Jitendra Mohan
Chief Executive Officer, Director
14% · $234M67% planned
Manuel Alba
Director
35% · $183MDisclosed plan
Stefan Dyckerhoff
Director
0.5% · $24.4MDisclosed plan
Philip Mazzara
General Counsel and Secretary
40% · $11.1M36% planned
Selling by month
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planTo cover taxesNo plan disclosed
Common questions
Is the Astera Labs, Inc. CEO selling stock?
Yes. Jitendra Mohan sold 1.27M shares ($234M, 14% of starting holdings) in the past 12 months, 67% of it under a trading plan disclosed in the filings.
Why are Astera Labs, Inc. insiders selling?
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 79% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 21% were to cover taxes and 0.3% had no disclosed plan. A trading plan schedules sales in advance.
Are any Astera Labs, Inc. insiders buying?
No. Officers and directors reported no purchases in the past 12 months.
How much of their stake did Astera Labs, Inc. insiders sell?
About 9.1% overall. As a group they still hold 91% of their starting shares. That covers the 12 months to Oct 8, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.
The evidence
Who sold8 officers and directors: amount, % of holdings, trading plan
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Sanjay Gajendra President and COO, Director | $319M 1.33M shares | 15% | 76% under a disclosed plan |
| Jitendra Mohan Chief Executive Officer, Director | $234M 1.27M shares | 14% | 67% under a disclosed plan |
| Manuel Alba Director | $183M 732K shares | 35% | Disclosed plan |
| Stefan Dyckerhoff Director | $24.4M 87K shares | 0.5% | Disclosed plan |
| Philip Mazzara General Counsel and Secretary | $11.1M 61K shares | 40% | 36% under a disclosed plan |
| Jack Lazar Director | $5.1M 23K shares | 23% | Disclosed plan |
| Michael Tate Chief Financial Officer | $3.1M 23K shares | 3.5% | No plan disclosed |
| Bethany Mayer Director | $271K 686 shares | 11% | Disclosed plan |
The full ownership picture12 of 12 insiders fully reconciled · 12 officers and directors
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 8, 2025 | Sold | Held Oct 8, 2026 | Still held | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Stefan DyckerhoffiIncludes unvested RSUs, amount not disclosed. Director | 17.22M | −87K | 17.13M | 99.5% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Stefan Dyckerhoff0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Jitendra MohaniIncludes unvested RSUs, amount not disclosed. Some sales match sales reported by Sanjay Gajendra exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it. Chief Executive Officer, Director | 9.30M | −1.27M | 8.06M | 87% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Jitendra Mohan0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Sanjay GajendraiIncludes unvested RSUs, amount not disclosed. Some sales match sales reported by Jitendra Mohan exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it. President and COO, Director | 9.09M | −1.33M | 7.64M | 84% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Sanjay Gajendra0shares vested or exercised −142Kgifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Manuel AlbaiIncludes unvested RSUs, amount not disclosed. Director | 2.12M | −732K | 1.39M | 65% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Manuel Alba0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Michael TateiIncludes unvested RSUs, amount not disclosed. Chief Financial Officer | 662K | −23K | 650K | 98% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Michael Tate0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Philip MazzaraiIncludes unvested RSUs, amount not disclosed. General Counsel and Secretary | 152K | −61K | 97K | 64% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Philip Mazzara | ||||||||||||||||||||||||||||||||||||||||||||
Jack LazariIncludes unvested RSUs, amount not disclosed. Director | 97K | −23K | 76K | 78% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Jack Lazar | ||||||||||||||||||||||||||||||||||||||||||||
Michael HurlstoniIncludes unvested RSUs, amount not disclosed. Director | 92K | 0 | 92K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Michael Hurlston | ||||||||||||||||||||||||||||||||||||||||||||
Bethany MayeriIncludes unvested RSUs, amount not disclosed. Director | 6.2K | −686 | 6.4K | +2.4% | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Bethany Mayer | ||||||||||||||||||||||||||||||||||||||||||||
Craig BarrattiIncludes unvested RSUs, amount not disclosed. Director | 6K | 0 | 6.8K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Craig Barratt | ||||||||||||||||||||||||||||||||||||||||||||
Germaine CotaiIncludes unvested RSUs, amount not disclosed. Started reporting during the period; starting holdings are from the Form 3. Chief Accting. Off. & VP, Fin. | 56 | 0 | 26K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Germaine Cota0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
Desmond LynchiIncludes unvested RSUs, amount not disclosed. Started reporting during the period; starting holdings are from the Form 3. Chief Financial Officer | 0 | 0 | 50K | no sales | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Desmond Lynch0shares vested or exercised 0gifted (net of own trusts) none reportedunvested awards, start → end
| ||||||||||||||||||||||||||||||||||||||||||||
12 of 12 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (12 exactly, 0 with a minor or footnoted difference). Percentages cover 11 of 12 officers and directors. Left out: Desmond Lynch (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.
What explains the selling$779M of sales by plan status, purpose, seller and month
Officer and director open-market sales: $779M across 3,530,260 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($165M), including tax-related sales outside a plan.
No plan disclosed · $2.4M
Sales with no 10b5-1 plan and no tax reference in the filing. $2.4M of it is Philip Mazzara. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Philip Mazzara, May 18, 2026
Taxes
$162M of sales (20.8%) cite tax obligations in their footnotes. Example: Philip Mazzara, Aug 17, 2026
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Sanjay Gajendra President and COO, Director | 1.33M | $319M | 76% | 41% | Nov 17, 2025 to Aug 17, 2026 |
| Jitendra Mohan Chief Executive Officer, Director | 1.27M | $234M | 67% | 30% | Nov 17, 2025 to Aug 17, 2026 |
| Manuel Alba Director | 732K | $183M | 100% | 23% | Dec 1, 2025 to Sep 1, 2026 |
| Stefan Dyckerhoff Director | 87K | $24.4M | 100% | 3% | Apr 17, 2026 to Sep 2, 2026 |
| Philip Mazzara General Counsel and Secretary | 61K | $11.1M | 36% | 1% | Nov 17, 2025 to Aug 17, 2026 |
| Jack Lazar Director | 23K | $5.1M | 100% | 0.7% | Nov 20, 2025 to Jun 4, 2026 |
| Michael Tate Chief Financial Officer | 23K | $3.1M | 0% | 0.4% | Nov 17, 2025 to Feb 17, 2026 |
| Bethany Mayer Director | 686 | $271K | 100% | 0.0% | Jun 24, 2026 to Jun 24, 2026 |
Sales by month
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $28.9M | $374K | $28.5M | $0 |
| Dec 2025 | $30.4M | $30.4M | $0 | $0 |
| Jan 2026 | $1.8M | $1.8M | $0 | $0 |
| Feb 2026 | $25.6M | $0 | $25.6M | $0 |
| Mar 2026 | $23.1M | $23.1M | $0 | $0 |
| Apr 2026 | $102M | $102M | $0 | $0 |
| May 2026 | $350M | $303M | $44.1M | $2.4M |
| Jun 2026 | $8.4M | $8.4M | $0 | $0 |
| Jul 2026 | $86.9M | $86.9M | $0 | $0 |
| Aug 2026 | $67.9M | $3.9M | $64.0M | $0 |
| Sep 2026 | $54.7M | $54.7M | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
Is this normal? Selling year by yearNot enough history to compare
Not enough history to compare: fewer than three earlier years of filings.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 8, 2026 Latest 12 months | 3.53M | 8 | $779M |
| Oct 8, 2025 1 year earlier | 7.26M | 9 | $765M |
| Oct 8, 2024 2 years earlier · filings don't cover the whole year | 485K | 6 | $23.0M |
| Oct 9, 2023 3 years earlier · filings don't cover the whole year | n/a | n/a | n/a |
| Oct 9, 2022 4 years earlier · filings don't cover the whole year | n/a | n/a | n/a |
| Oct 9, 2021 5 years earlier · filings don't cover the whole year | n/a | n/a | n/a |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Known gaps and uncertaintyEvery officer and director reconciles
Sources and methodology196 filings from SEC EDGAR, and how we read them
All 196 Forms 3, 4 and 5 filed for Astera Labs, Inc. (SEC CIK 1736297) from Mar 19, 2024 to Sep 3, 2026, retrieved from SEC EDGAR on Oct 8, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
Former or inactive filers (1)No filing in 18 months; last reported balances, not in any total
| Name | Last filed | Last reported balance |
|---|---|---|
| SUTTER HILL VENTURES | Aug 19, 2024 | 13,268,180 shares, last reported balance as of Aug 15, 2024 |